Fundamental & clinical pharmacology · 2026
Real-World Use of Dupilumab in Atopic Dermatitis: Observational Study Results Linked to SNDS.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dupuy Alain, Fougerousse Anne-Claire, Bécherel Pierre-André, Droitcourt Catherine, Kerbrat Sandrine, Mahieu Aymeric, Allali Noémie, Vataire Anne-Lise, Thénié Claire, Helman Nathalie, Lacour Jean-Philippe
Аннотация
BACKGROUND: Dupilumab is reimbursed in France for adult patients with moderate-to-severe atopic dermatitis (AD), in cases of failure, intolerance or contraindication to cyclosporin A (CsA). The French National Authority for Health requested collection of data on dupilumab-treated patients' characteristics and prior systemic treatments to examine conformity with the reimbursement scope.
OBJECTIVES: This study aimed to describe characteristics of adult patients initiating dupilumab for AD and their prior lines of systemic treatments with a focus on CsA.
METHODS: Our dual approach combined information from two databases: the SNDS database allowing access to nationwide prescriptions for dupilumab (DUPIXAM study) and data collected by a sponsor-initiated multicentre, cross-sectional, observational study on patients initiating dupilumab for AD (MOVE study).
RESULTS: From December 2019 to May 2021, 594 eligible patients were included in the MOVE study. In parallel, from March 2019 to December 2020, 3216 adult patients with presumed indications of moderate-to-severe AD were extracted from SNDS. Patients' characteristics were quite similar: median age was > 34 years old and they were gender balanced. More than 69% of MOVE patients had severe AD and 82.8% had at least one atopic comorbidities. Previous systemic treatments were used by over 62.8% of patients, of whom over 75.0% had received CsA. Among the 25.0% without previous CsA, the indirect combinatory approach made it possible to estimate an unbiased proportion of CsA contraindications in 71.0% of patients.
CONCLUSION: This joint analysis provided a detailed view of real-world conditions of dupilumab use in France through the completeness of data, and constitutes a proof of concept that could be extended to address other health-related questions.
OBJECTIVES: This study aimed to describe characteristics of adult patients initiating dupilumab for AD and their prior lines of systemic treatments with a focus on CsA.
METHODS: Our dual approach combined information from two databases: the SNDS database allowing access to nationwide prescriptions for dupilumab (DUPIXAM study) and data collected by a sponsor-initiated multicentre, cross-sectional, observational study on patients initiating dupilumab for AD (MOVE study).
RESULTS: From December 2019 to May 2021, 594 eligible patients were included in the MOVE study. In parallel, from March 2019 to December 2020, 3216 adult patients with presumed indications of moderate-to-severe AD were extracted from SNDS. Patients' characteristics were quite similar: median age was > 34 years old and they were gender balanced. More than 69% of MOVE patients had severe AD and 82.8% had at least one atopic comorbidities. Previous systemic treatments were used by over 62.8% of patients, of whom over 75.0% had received CsA. Among the 25.0% without previous CsA, the indirect combinatory approach made it possible to estimate an unbiased proportion of CsA contraindications in 71.0% of patients.
CONCLUSION: This joint analysis provided a detailed view of real-world conditions of dupilumab use in France through the completeness of data, and constitutes a proof of concept that could be extended to address other health-related questions.